|Bid||9.05 x 900|
|Ask||9.13 x 900|
|Day's Range||9.05 - 9.25|
|52 Week Range||6.13 - 10.93|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BX001 is a topically administered gel comprised of a cocktail of naturally occurring phage targeting Cutibacterium acnes (C. acnes, formerly taxonomically classified as Propionibacterium acnes, or P. acnes), a bacterium implicated in the pathophysiology of acne vulgaris. The primary endpoints of the randomized, double-blind, dose-ranging, vehicle-controlled study are safety and tolerability.
- Data presented at the presidential plenary translational session of the AASLD conference
NEW YORK , Nov. 12, 2019 /PRNewswire/ -- Stone Street Group has announced it has initiated coverage on BiomX Inc (NYSE: PHGE). The full report can be found here: PHGE Report Key Report Highlights: Chardan ...
BiomX Inc. (NYSE: PHGE), a microbiome company developing both natural and engineered phage therapies, today announced the election of Russell G. Greig, Ph.D., as Chairman of the Board of Directors and Lynne Sullivan as Board Director. Dr. Greig brings extensive leadership experience in the pharmaceutical and biotech sectors in research and development and business roles, including three decades at GlaxoSmithKline, most recently as President of SR One, GlaxoSmithKline’s corporate venture group. Ms. Sullivan brings extensive expertise in finance having served in senior roles in several leading pharmaceutical and biotech companies including as Senior Vice President of Finance for Biogen, where she worked for over a decade.
BiomX Inc. , a microbiome company developing both natural and engineered phage therapies, today announced that BiomX’s Chief Medical Officer, Sailaja Puttagunta, M.D., will present pre-clinical data from the company’s liver program at the plenary session of the American Association for The Study of Liver Diseases taking place in Boston, Massachusetts from November 8 - November 12, 2019.